Pathnostics
Pathnostics is a leading precision diagnostic testing and development company established in 2011. It specializes in solutions for infectious disease and cancer diagnostics, providing advanced tests that include histopathology, cytology, molecular tests, and innovative diagnostic technologies. The company is committed to transforming diagnostic and therapeutic dilemmas through innovative solutions, robust science, and clinical evidence, aiming to improve patient outcomes across various healthcare settings. Pathnostics actively contributes to antimicrobial resistance awareness and antibiotic stewardship by offering advanced diagnostic tests like Guidance® UTI, which detects pathogens and antibiotic resistance genes, supporting targeted therapy and reducing inappropriate antibiotic use.
Industries
Nr. of Employees
medium (51-250)
Products
Comprehensive specialty diagnostic test menu
Portfolio of diagnostic tests for urology, gastrointestinal, and women’s health indications including molecular assays, culture-based tests (standard and expanded), proteomic identification, histopathology, and cytology.
Comprehensive specialty diagnostic test menu
Portfolio of diagnostic tests for urology, gastrointestinal, and women’s health indications including molecular assays, culture-based tests (standard and expanded), proteomic identification, histopathology, and cytology.
Services
Central laboratory testing for infectious disease and pathology diagnostics using integrated molecular assays, culture methods (including EQUC), proteomic identification, histopathology, and cytology for provider-ordered specimens.
A two-step diagnostic workflow that first identifies pathogens and resistance markers via multiplex PCR and then reports pooled phenotypic antibiotic susceptibility of the specimen community against a panel of antibiotics to inform targeted therapy for complicated, recurrent, or polymicrobial UTIs.
Collaborative design and conduct of clinical validation and utility studies for diagnostic tests, including publication of comparative performance and clinical outcome studies.
Central laboratory testing for infectious disease and pathology diagnostics using integrated molecular assays, culture methods (including EQUC), proteomic identification, histopathology, and cytology for provider-ordered specimens.
A two-step diagnostic workflow that first identifies pathogens and resistance markers via multiplex PCR and then reports pooled phenotypic antibiotic susceptibility of the specimen community against a panel of antibiotics to inform targeted therapy for complicated, recurrent, or polymicrobial UTIs.
Collaborative design and conduct of clinical validation and utility studies for diagnostic tests, including publication of comparative performance and clinical outcome studies.
Expertise Areas
- Infectious disease diagnostics
- Urinary tract infection diagnostics and management
- Integrated molecular and phenotypic susceptibility testing for polymicrobial infections
- Antimicrobial-resistance detection and stewardship support
Key Technologies
- Multiplex PCR
- DNA sequencing
- Genotypic antimicrobial-resistance gene detection
- Pooled phenotypic susceptibility testing
News & Updates
Participation in the Oklahoma Society of Urology Associates conference in Oklahoma City, OK.
An overview of recent developments in UTI diagnostics using multi-omics techniques.
Completed eight clinical studies involving over 73,000 subjects demonstrating the efficacy of Guidance® UTI platform.
Participation in the Oklahoma Society of Urology Associates conference in Oklahoma City, OK.
An overview of recent developments in UTI diagnostics using multi-omics techniques.
Completed eight clinical studies involving over 73,000 subjects demonstrating the efficacy of Guidance® UTI platform.